Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular targets for neuroprotection.

Serge Przedborski1

  • 1Departments of Neurology and Pathology, and the Center for Neurobiology and Behavior, Columbia University, New York, NY 10032, USA. SP30@columbia.edu

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
|October 30, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated Gait and Pose Analysis Utilizing Computer Vision for Parkinsonian Behavioral Phenotyping in Mice.

bioRxiv : the preprint server for biology·2026
Same author

Detection of phosphorylated α-synuclein in skin - Authors' reply.

The Lancet. Neurology·2026
Same author

Targeted antisense oligonucleotide treatment rescues developmental alterations in spinal muscular atrophy organoids.

Nature communications·2025
Same author

Parkinson's Disease, Second Edition.

Cold Spring Harbor perspectives in medicine·2025
Same author

Rare <i>PANK2</i> variants and pantothenate-kinase-associated neurodegeneration in the Dominican Republic.

Brain communications·2025
Same author

Single-cell transcriptomic landscape of the neuroimmune compartment in amyotrophic lateral sclerosis brain and spinal cord.

Acta neuropathologica·2025

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. Experimental models are crucial for understanding ALS and testing therapies targeting apoptosis for neuroprotection.

Area of Science:

  • Neuroscience
  • Pathology
  • Pharmacology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a fatal paralytic neurodegenerative disorder.
  • Apoptosis, or programmed cell death, is increasingly recognized as a key factor in ALS pathogenesis.
  • Experimental models are essential for studying ALS and developing treatments.

Purpose of the Study:

  • To review the role of apoptosis in ALS pathogenesis.
  • To highlight the utility of experimental ALS models in therapeutic development.
  • To discuss the potential of targeting apoptosis for neuroprotection in ALS.

Main Methods:

  • Utilizing transgenic rodent models expressing mutant superoxide dismutase-1.
  • Investigating the apoptosis machinery as a therapeutic target.

Related Experiment Videos

  • Analyzing pre-clinical data from experimental ALS models.

    • Main Results:

    • Experimental models provide critical insights into ALS pathogenesis.
    • The apoptosis pathway presents multiple targets for therapeutic intervention.
    • Pre-clinical studies are foundational for developing effective ALS therapies.

    Conclusions:

    • Targeting apoptosis in experimental ALS models shows promise for neuroprotection.
    • Further research in pre-clinical models can lead to effective treatments for ALS.
    • Understanding apoptosis is key to developing therapies for this devastating neurodegenerative disease.